Medical Condition News

RSS
Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

Study: Only 30% of people with neuroendocrine tumors consider living longer as top priority

Study: Only 30% of people with neuroendocrine tumors consider living longer as top priority

Researchers show link between a debilitating heart condition and COVID-19 infection, vaccination

Researchers show link between a debilitating heart condition and COVID-19 infection, vaccination

Light therapy could be a promising non-drug treatment option for multiple sclerosis-related fatigue

Light therapy could be a promising non-drug treatment option for multiple sclerosis-related fatigue

Novel wearable device can monitor physiological parameters associated with heart failure in real-time

Novel wearable device can monitor physiological parameters associated with heart failure in real-time

Exposure to extremely hot or cold temperatures increases heart disease deaths

Exposure to extremely hot or cold temperatures increases heart disease deaths

Novel drug shows early potential in combating multiple myeloma

Novel drug shows early potential in combating multiple myeloma

Simplified treatment regimen results in dramatic decrease in early deaths from acute promyelocytic leukemia

Simplified treatment regimen results in dramatic decrease in early deaths from acute promyelocytic leukemia

Many genetic disorders respond well to specialized gene therapy

Many genetic disorders respond well to specialized gene therapy

Study provides new insights for the future development of oral insulin pill

Study provides new insights for the future development of oral insulin pill

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Novel monoclonal antibody therapy shows promising results in patients with moderate to severe atopic dermatitis

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

Forxiga (dapagliflozin) approved in Great Britain for symptomatic chronic heat failure across the full spectrum of left ventricular ejection fraction

Aging influences the diagnosis and treatment of heart attacks in patients over age 75

Aging influences the diagnosis and treatment of heart attacks in patients over age 75

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

A-HIPI decision model can predict survival in adults with advanced-stage Hodgkin lymphoma

How the COVID-19 pandemic impacted the treatment pancreatic cancer patients

How the COVID-19 pandemic impacted the treatment pancreatic cancer patients

Reports of Mpox disease following recent vaccination

Reports of Mpox disease following recent vaccination

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.